Table 1 Pivotal studies - DME (YOSEMITE and RHINE), nAMD (TENAYA and LUCERNE)
From: Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
Study | Disease | Study Design | Number of Patients (Faricimab) | Number of Patients (Aflibercept) | Key Findings |
|---|---|---|---|---|---|
YOSEMITE (6) | DME | Randomized, double-blind, non-inferiority (Phase 3) | 628 | 312 | Faricimab non-inferior in visual gains and anatomical improvement compared to aflibercept every 8 weeks. Low rates of intraocular inflammation |
RHINE (6) | DME | Randomized, double-blind, non-inferiority (Phase 3) | 636 | 315 | Faricimab non-inferior in visual gains and anatomical improvement compared to aflibercept every 8 weeks. Low rates of intraocular |
TENAYA (13) | nAMD | Randomized, double-blind, non-inferiority (Phase 3) | 334 | 337 | Faricimab comparable to Aflibercept in visual gains and anatomical improvement at treatment intervals up to 16 weeks. Low rates of intraocular inflammation |
LUCERNE (13) | nAMD | Randomized, double-blind, non-inferiority (Phase 3) | 331 | 327 | Faricimab comparable to Aflibercept in visual gains and anatomical improvement at treatment intervals up to 16 weeks. Low rates of intraocular inflammation |